Altimmune's pemvidutide faces Q3 alcohol-disorder readout after enrollment closed early
The RECLAIM Phase 2 trial completed enrollment ahead of schedule, and its heavy-drinking-days endpoint will test pemvidutide beyond the obesity and MASH programs that anchor Altimmune's pipeline.
Executive Summary
- Altimmune is heading into a topline readout for pemvidutide in alcohol use disorder, a third indication for a drug the company is otherwise advancing through liver-disease development.
- The trial finished enrollment at its target and moved to an active, non-recruiting status ahead of its original schedule, putting the readout on track rather than at risk.
- The GLP-1 receptor mechanism is broadly validated in metabolic disease, but only one other Phase 3 program shares both this target and this specific psychiatric indication, leaving pemvidutide's result relatively unbenchmarked in alcohol use disorder itself.
- A result that shows a meaningful reduction in heavy drinking days versus placebo would extend the drug's evidence base into a new therapeutic category and inform how the same mechanism is read across Altimmune's broader pipeline.
The catalyst
Altimmune said in a March 5, 2026 corporate update that topline data from its RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder are expected in the third quarter of 2026. The trial, registered as NCT06987513, randomizes roughly 100 adults with moderate-or-greater alcohol use disorder and overweight or obesity to pemvidutide or placebo over a 24-week treatment period. The primary endpoint is the change from baseline in average heavy drinking days per week, using the timeline followback method, with a heavy drinking day defined as five or more drinks for men and four or more for women. Altimmune+1Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business UpdatesMar 5, 2026RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightNCT06987513
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Trial status
The trial completed enrollment at its 100-patient target in November 2025 and shifted from Recruiting to Active, not recruiting that same month. Its primary completion date moved from September 30, 2026 to May 1, 2026, a pull-forward of about four months rather than a delay. The enrollment level held flat at 100 patients against a 100-patient target, a result the operational model reads as a routine, on-target close rather than a deviation. NCT06987513RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightNCT06987513
Pipeline context
Alcohol use disorder is pemvidutide's third indication. Altimmune reported positive 48-week data from its IMPACT Phase 2b trial in MASH in December 2025, with statistically significant improvements in liver fibrosis and inflammation markers, and the FDA granted the drug Breakthrough Therapy Designation in MASH based on 24-week data from that trial. The company said it is finalizing plans for a global Phase 3 MASH trial in 2026. The FDA separately granted pemvidutide Fast Track designation for alcohol use disorder, first disclosed in August 2025 and reaffirmed in subsequent company statements through March 2026. AltimmuneAltimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business UpdatesMar 5, 2026
The competitive frame
Pemvidutide is not first to test a GLP-1-pathway drug in alcohol use disorder: Eli Lilly's brenipatide, also a GLP-1R-targeting peptide, is running two Phase 3 trials in the same indication, including one measuring the same drinking-pattern outcome by timeline followback. That makes brenipatide the closest direct comparator on target, modality and indication. Beyond that, the alcohol use disorder field is dominated by non-GLP-1 mechanisms, including naltrexone-based opioid-receptor approaches and an orexin antagonist in Phase 2, none of which share pemvidutide's target class. No resolved trial combining the GLP-1R target with this indication currently exists, and the broader GLP-1R agonist class remains far more mature in obesity and type 2 diabetes than in alcohol use disorder, where pemvidutide's own readout would be an early data point rather than a confirmation of an established pattern.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.